Inhibrx Biosciences (INBX) Long-Term Debt Issuances (2025)
Inhibrx Biosciences (INBX) reported Long-Term Debt Issuances of $100.0 million for Q1 2025.
Inhibrx Biosciences (INBX) Long-Term Debt Issuances (2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 1 years of Long-Term Debt Issuances data on file, last reported at $100.0 million in Q1 2025.
- Long-Term Debt Issuances for Q1 2025 came in at $100.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $100.0 million (changed N/A YoY), and the FY2025 annual result was $100.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances held at $100.0 million in Q1 2025 per INBX's latest filing.
- Over five years, Long-Term Debt Issuances peaked at $100.0 million in Q1 2025 and troughed at $100.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 99.97 Mn |
| Mar 31, 2025 | 99.97 Mn |